Alzheimer ’ s: Frequent Relocations May Speed Decline

Credit: Thinkstock   Specialized care is needed at different stages of dementia. Frequently, the only way to provide that kind of care is to move the person to either a memory unit or a family home, while supplementing care provided by family members with paid in-home caregivers. In many cases, it ’s simply unrealistic to expect to never have to relocate someone who has dementia.     At the same time, frequently moving...
Source: Carol Bradley Bursack's SharePosts - Category: Geriatrics Authors: Source Type: blogs

Related Links:

Drugs that doctors often use in the treatment of overactive bladder, gastrointestinal conditions, and depression may increase dementia risk by almost half.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
ANAHEIM, CA - Researchers are reporting early success in adapting a new method...Read more on AuntMinnie.comRelated Reading: PiB-PET study strengthens link between amyloid, dementia High amyloid levels on PET may indicate early Alzheimer's PiB-PET could open window on common meningiomas SNMMI: PET shows tau may be Alzheimer's catalyst SNMMI: PiB-PET finds unique Down syndrome trait
Source: Headlines - Category: Radiology Source Type: news
Drugs that doctors often use in the treatment of overactive bladder, gastrointestinal conditions, and depression may increase dementia risk by almost half.
Source: Parkinson's Disease News From Medical News Today - Category: Neurology Tags: Alzheimer's / Dementia Source Type: news
The Src kinase Fyn plays critical roles in memory formation and Alzheimer ’s disease. Its targeting to neuronal dendrites is regulated by Tau via an unknown mechanism. As nanoclustering is essential for efficient signaling, we used single-molecule tracking to characterize the nanoscale distribution of Fyn in mouse hippocampal neurons, and manipulated the expression of T au to test whether it controls Fyn nanoscale organization. We found that dendritic Fyn exhibits at least three distinct motion states, two of them associated with nanodomains. Fyn mobility decreases in dendrites during neuronal maturation, suggesting ...
Source: eLife - Category: Biomedical Science Tags: Cell Biology Neuroscience Source Type: research
Alzheimer’s disease (AD) therapies predominantly focus on β-amyloid (Aβ), but Aβ effects may be maximal before clinical symptoms appear. Downstream of Aβ, dendritic spine loss correlates most strongly with cognitive decline in AD. Rho-associated kinases (ROCK1 and ROCK2) regulate the actin cytoskeleton, and ROCK1 and ROCK2 protein abundances are increased in early AD. Here, we found that the increased abundance of ROCK1 in cultured primary rat hippocampal neurons reduced dendritic spine length through a myosin-based pathway, whereas the increased abundance of ROCK2 induced spine loss through the s...
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Tags: STKE Research Articles Source Type: news
Title: Cancer Survivors May Have Lower Odds for DementiaCategory: Health NewsCreated: 6/21/2019 12:00:00 AMLast Editorial Review: 6/24/2019 12:00:00 AM
Source: MedicineNet Alzheimer - Category: Geriatrics Source Type: news
Conclusion: Textures of the hippocampus, precuneus and posterior cingulate cortex predicted conversion from MCI to Alzheimer disease at an earlier time point and with higher accuracy than hippocampal volume. PMID: 31228173 [PubMed - as supplied by publisher]
Source: Journal of Psychiatry and Neuroscience - Category: Psychiatry Tags: J Psychiatry Neurosci Source Type: research
Owing to its worldwide spread, Alzheimer's disease (AD) was identified as a “global public health priority’’ by the World Health Organization in 2015.1 At that time, an estimated 47 million people were affected by AD and other dementias worldwide, a figure that is expected to reach 75 million by 2030 and 131 million by 2050. Dementia is a neurodegenerative illness who se prevalence increases with age.2 The 4.4% (3.2% in men, 5.8% in women) prevalence of dementia in 1996 in Taiwan3 increased to 6.0% as of 2010–2015.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Source Type: research
Lewy body dementia (LBD) is a major public health problem worldwide. Prevalence of Lewy body dementia (LBD) is second only to Alzheimer's disease (AD) among people with neurodegenerative dementia.1 LBD cause earlier mortality,2 earlier nursing home admissions, poorer quality-of-life, higher costs,3 more frequent falls, and more caregivers ’ burden than AD. LBD include two overlapping clinical syndromes, dementia with Lewy bodies (DLB) and Parkinson's disease (PD) dementia (PDD). They cause more frequent and more intense neuropsychiatric symptoms including visual hallucinations, delusions, agitation, and depression than AD.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Regular Research Article Source Type: research
AbstractPurpose of reviewThe goal of the current review is to provide an update on the management of agitation in persons with dementia with a focus on pharmacological management of persons with Alzheimer ’s disease.Recent findingsAs consistently effective and safe pharmacologic interventions are still lacking, identifying and addressing medical and environmental precipitants remain a priority. Acetylcholinesterase inhibitors and memantine should be initiated to enhance cognition, and if present, management of insomnia or sundowning with trazodone is indicated. If agitation persists, treatment with citalopram can be ...
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research
More News: Alzheimer's | Dementia